User login
Aczone Gel 7.5%
Allergan announces US Food and Drug Administration approval of Aczone (dapsone) Gel 7.5% for the treatment of acne vulgaris in patients 12 years and older. The new formula contains a higher concentration of dapsone (versus the 5% concentration) with the same tolerability and enhanced efficacy to treat both inflammatory and noninflammatory acne. Once-daily application and the pump delivery system aid in improving adherence to treatment. For more information, visit www.aczonehcp.com.
Cutanea Life Sciences
Cutanea Life Sciences, Inc (CLS), an emerging US prescription product development company, unveils its new website, www.cutanea.com, to the dermatology community. The new digital presence demonstrates the company’s intent to change the way customers think about a valued dermatology partner. The CLS management team is well versed in the development and commercialization of dermatologic therapies. With product candidates in various stages of development that cover an array of skin conditions such as acne, rosacea, psoriasis, and warts caused by human papillomavirus, CLS is committed to focusing on underserved patient needs, which will help health care professionals optimize their practice time through CLS’s dermatologic products and services.
Sernivo Spray 0.05%
Promius Pharma, LLC, announces US Food and Drug Administration approval of Sernivo (betamethasone dipropionate) Spray 0.05%, a corticosteroid for the treatment of mild to moderate plaque psoriasis in patients 18 years and older. Sernivo Spray should be used twice daily for 4 weeks and not beyond. In clinical trials more participants showed treatment success with Sernivo Spray versus vehicle at day 15 and day 29. For more information, visit www.promiuspharma.com.
Teflaro
Allergan announces that the US Food and Drug Administration has accepted for filing a supplemental new drug application for Teflaro (ceftaroline fosamil) to expand the label to include the treatment of children 2 months and older with acute bacterial skin and skin structure infections (ABSSSI) including infections caused by methicillin-resistant Staphylococcus aureus and community-acquired bacterial pneumonia (CABP) caused by Staphylococcus pneumoniae and other designated susceptible bacteria. Teflaro is a bactericidal cephalosporin with activity against both gram-positive and gram-negative pathogens. Teflaro is already approved for ABSSSI and CABP in adult patients. For more information, visit www.teflaro.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.
Aczone Gel 7.5%
Allergan announces US Food and Drug Administration approval of Aczone (dapsone) Gel 7.5% for the treatment of acne vulgaris in patients 12 years and older. The new formula contains a higher concentration of dapsone (versus the 5% concentration) with the same tolerability and enhanced efficacy to treat both inflammatory and noninflammatory acne. Once-daily application and the pump delivery system aid in improving adherence to treatment. For more information, visit www.aczonehcp.com.
Cutanea Life Sciences
Cutanea Life Sciences, Inc (CLS), an emerging US prescription product development company, unveils its new website, www.cutanea.com, to the dermatology community. The new digital presence demonstrates the company’s intent to change the way customers think about a valued dermatology partner. The CLS management team is well versed in the development and commercialization of dermatologic therapies. With product candidates in various stages of development that cover an array of skin conditions such as acne, rosacea, psoriasis, and warts caused by human papillomavirus, CLS is committed to focusing on underserved patient needs, which will help health care professionals optimize their practice time through CLS’s dermatologic products and services.
Sernivo Spray 0.05%
Promius Pharma, LLC, announces US Food and Drug Administration approval of Sernivo (betamethasone dipropionate) Spray 0.05%, a corticosteroid for the treatment of mild to moderate plaque psoriasis in patients 18 years and older. Sernivo Spray should be used twice daily for 4 weeks and not beyond. In clinical trials more participants showed treatment success with Sernivo Spray versus vehicle at day 15 and day 29. For more information, visit www.promiuspharma.com.
Teflaro
Allergan announces that the US Food and Drug Administration has accepted for filing a supplemental new drug application for Teflaro (ceftaroline fosamil) to expand the label to include the treatment of children 2 months and older with acute bacterial skin and skin structure infections (ABSSSI) including infections caused by methicillin-resistant Staphylococcus aureus and community-acquired bacterial pneumonia (CABP) caused by Staphylococcus pneumoniae and other designated susceptible bacteria. Teflaro is a bactericidal cephalosporin with activity against both gram-positive and gram-negative pathogens. Teflaro is already approved for ABSSSI and CABP in adult patients. For more information, visit www.teflaro.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.
Aczone Gel 7.5%
Allergan announces US Food and Drug Administration approval of Aczone (dapsone) Gel 7.5% for the treatment of acne vulgaris in patients 12 years and older. The new formula contains a higher concentration of dapsone (versus the 5% concentration) with the same tolerability and enhanced efficacy to treat both inflammatory and noninflammatory acne. Once-daily application and the pump delivery system aid in improving adherence to treatment. For more information, visit www.aczonehcp.com.
Cutanea Life Sciences
Cutanea Life Sciences, Inc (CLS), an emerging US prescription product development company, unveils its new website, www.cutanea.com, to the dermatology community. The new digital presence demonstrates the company’s intent to change the way customers think about a valued dermatology partner. The CLS management team is well versed in the development and commercialization of dermatologic therapies. With product candidates in various stages of development that cover an array of skin conditions such as acne, rosacea, psoriasis, and warts caused by human papillomavirus, CLS is committed to focusing on underserved patient needs, which will help health care professionals optimize their practice time through CLS’s dermatologic products and services.
Sernivo Spray 0.05%
Promius Pharma, LLC, announces US Food and Drug Administration approval of Sernivo (betamethasone dipropionate) Spray 0.05%, a corticosteroid for the treatment of mild to moderate plaque psoriasis in patients 18 years and older. Sernivo Spray should be used twice daily for 4 weeks and not beyond. In clinical trials more participants showed treatment success with Sernivo Spray versus vehicle at day 15 and day 29. For more information, visit www.promiuspharma.com.
Teflaro
Allergan announces that the US Food and Drug Administration has accepted for filing a supplemental new drug application for Teflaro (ceftaroline fosamil) to expand the label to include the treatment of children 2 months and older with acute bacterial skin and skin structure infections (ABSSSI) including infections caused by methicillin-resistant Staphylococcus aureus and community-acquired bacterial pneumonia (CABP) caused by Staphylococcus pneumoniae and other designated susceptible bacteria. Teflaro is a bactericidal cephalosporin with activity against both gram-positive and gram-negative pathogens. Teflaro is already approved for ABSSSI and CABP in adult patients. For more information, visit www.teflaro.com.
If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.
